Astrum Therapeutics to begin clinical trials on Type 2 diabetes compounds
Friday, 29 July, 2005
Brisbane biotech BioProspect (ASX:BPO) has hit heavy cloud in its attempts to secure international partners to commercialise its novel plant-derived pesticides, but feels the sun is beginning to shine on its investment in Astrum Therapeutics.
BioProspect bought a one-third stake in Astrum on April 1, and the Melbourne drug-developer has announced it is moving to synthesise sufficient quantities of its two candidate compounds for treating Type 2 (non-insulin dependent) diabetes for clinical trials.
Astrum will begin recruiting volunteers for the trials by the end of the year -- it has not revealed the molecular targets for the molecules, but said they prevent the death of insulin-secreting pancreatic islet cells.
The company has also completed patent applications for combination therapies of its compounds, targeting the three major metabolic problems associated with type 2 diabetes -- cardiovascular disease, inflammation and neurological complications.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
